Japan – Moving Beyond the ‘Blockbuster’ Legacy to Reshape Kidney Disease Treatment Through a Dual-Mechanism Approach: Dialogue with HighTide Therapeutics’ CMO Dr. Filip Surmont

Moving Beyond the ‘Blockbuster’ Legacy to Reshape Kidney Disease Treatment Through a Dual-Mechanism Approach: Dialogue with HighTide Therapeutics’ CMO Dr. Filip Surmont

HONG KONG, Apr 2, 2026 – (ACN Newswire) –Throughout the landscape of international biotech business, the visit of a senior executive frequently acts as a “barometer”– offering insights into a business’s pipeline capacity and showing how market veterans evaluate the sector’s future.

A clear signal of the business’s development got here in February 2026, when HighTide Therapeutics (2511. HK) revealed a prominent executive consultation: Dr. Filip Surmont signed up with the business as Chief Medical Officer (CMO).

For specialists in the cardiovascular, kidney, and metabolic fields, this is a name that brings genuine weight. Over a profession covering 3 years, Dr. Surmont has actually held senior medical management functions at international giants consisting of Wyeth, Pfizer, and AstraZeneca. Amongst his most significant contributions was his function in the international tactical advancement of the SGLT-2 inhibitor dapagliflozin– a landmark effort that needed close cooperation throughout functions and locations within a big international company. As part of a gifted cross-functional group, he assisted form the method that placed dapagliflozin as an international metabolic hit, eventually reaching $8.405 billion USD in sales in 2025.

Especially, simply a couple of months previously, HighTide Therapeutics’ core item, HTD1801, had actually outshined dapagliflozin throughout several crucial cardiovascular, kidney, and metabolic endpoints in a head-to-head Phase III medical trial for type 2 diabetes mellitus (T2DM).

For Dr. Surmont, transitioning from handling a ruling “blockbuster” to signing up with a “opposition” Chinese biotech was far from coincidental. What drew him out of his convenience zone was not simply HTD1801’s strong glucose-lowering efficiency, however likewise the advancement capacity this brand-new molecular entity (NME) has actually displayed in cardiovascular, kidney and metabolic (CKM) illness in basic, and persistent kidney illness (CKD) more particularly– driven by an essentially separated pathophysiological systems.

I. Challenging Clinical Complacency in CKD: The Quest for True Reversal

Within the medical neighborhood, persistent kidney illness (CKD) has actually long provided aggravation. As soon as the kidney function starts to decrease, it normally weakens gradually and irreversibly gradually, leaving most clients dealing with dialysis or kidney transplant as an ultimate result.

“There has long been a degree of complacency in CKD treatment among physicians, patients, and even caregivers,” Dr. Surmont kept in mind specifically. “A mindset has taken hold that the progressive decline in renal function with age is inevitable. I’ve been striving to change this mindset throughout my career, both during my time at multinational pharmaceutical companies and now.”

Existing basic treatments– consisting of ACE inhibitors/ARBs and the extensively utilized SGLT-2 inhibitors– have actually shown effectiveness in slowing illness development, yet disappoint stopping or reversing the underlying pathology. They can considerably decrease the rate of decrease in the approximated glomerular filtering rate (eGFR), purchasing clients important time, however stop working to modify the terminal trajectory towards kidney failure.

Additional making complex the scientific image is the multi-factorial nature of CKD. Taking diabetic kidney illness (DKD) brought on by T2DM as an example, besides pathophysiological aspects driven by metabolic dysfunction, it is made complex by interconnected and extremely intricate aspects such as hemodynamic perturbances, persistent swelling, fibrosis, and other non-diabetic aspects that sustain each other to get worse illness diagnosis.

Existing standard-of-care drugs frequently resolve just one measurement of the illness by controling hemodynamics or a single metabolic path, making it hard to thoroughly deal with the inflammatory damage in the kidney microenvironment.

II. Inside the Mechanism: Remodeling Renal Architecture by means of a Dual Metabolic and Anti-inflammatory Pathway

The development of HTD1801 offers a brand-new secret to breaking this deadlock.

As an oral anti-inflammatory and metabolic modulator (AIMM) individually established by HighTide Therapeutics, HTD1801 shows a distinct restorative capacity at the tiny level as compared to standard drugs. Instead of counting on a single system, it takes a “two-pronged” method by triggering AMPK (adenosine monophosphate-activated protein kinase) and preventing the NLRP3 inflammasome.

Dr. Surmont has complete self-confidence in the clinical reasoning underpinning this system: “This drug acts simultaneously on two critical levels: beyond blood sugar, it improves overall metabolic efficiency at its source; at the same time, it directly suppresses the underlying chronic inflammation that drives organ damage.”

Taking a deep dive into its system of action, HTD1801’s double system exactly targets numerous microstructures within the kidney. “This is reflected across different renal compartments,” Dr. Surmont described. “From the filtering glomeruli and the structural interstitium to the reabsorptive tubules, and even podocytes—the vital gatekeepers of the filtration barrier, the dual action of AMPK activation and NLRP3 inhibition has demonstrated stronger-than-expected protective benefits.”

This mechanistic reasoning, covering from metabolic guideline to organ-level security, has actually eventually been confirmed by scientific information.

At the 2025 American Society of Nephrology (ASN) Annual Meeting, HighTide Therapeutics provided as a late breaker Phase III scientific research study information in T2DM clients with moderate kidney problems. The outcomes caught the market’s attention: compared to the placebo group, the HTD1801 group showed a considerable and sustainable distinction in annualized eGFR slope of +9.81 ml/min/1.73 m TWO/ year.

In the eyes of nephrologists, a “positive slope” on the eGFR curve is a strong and distinct signal, recommending the possibility of early structural healing.

“What we need to do next is confirm that this eGFR repair effect observed in DKD also holds true for CKD patients not driven by diabetes,” Dr. Surmont exposed, suggesting that pertinent scientific research studies are currently underway, with more in-depth information anticipated to verify this cross-etiology restorative capacity.

III. From “Rescue” to “Prevention”: Advancing a Holistic Cardiorenal Metabolic (CKM) Mindset

Dr. Surmont gives HighTide Therapeutics more than simply scientific competence; he brings a “game-changing” mindset that goes beyond a single-drug viewpoint.

Another career-defining turning point for Dr. Surmont was his management function in assisting improve worldwide asthma treatment standards. Historically, asthma management depended on short-acting bronchodilators for “rescue” just upon worsening of signs and shortness of breath. Dr. Surmont proposed and confirmed the “Anti-Inflammatory Reliever (AIR)” technique a modern-day asthma management technique that utilizes a mix breathed in corticosteroids and a bronchodilator as a reducer– dealing with both the intense bronchospasm and the underlying respiratory tract swelling with every dosage, in contrast to conventional brief acting dilator-only relief. This shift eventually benefited roughly 120 million clients around the world and improved treatment paradigms.

Now, dealing with CKD, he sees the exact same chance for a paradigm-shifting development.

Offered HTD1801’s strong capacity to fix moderate kidney problems, future scientific standards might fairly advise starting treatments early, when eGFR is still at a fairly high level. By developing a favorable trajectory for kidney function healing early in the illness, there is hope that many clients can entirely prevent the looming danger of dialysis.

From a health-economics point of view, this would reallocate health care costs: moving funds far from pricey late-stage interventions (such as dialysis and cardiac arrest rescue) towards extremely economical early treatment, consequently producing significant health care expense savings for society and minimizing clients’ monetary concern for late-stage interventions.

Dr. Surmont likewise highly supporters for a holistic management method to “Cardiovascular-Kidney-Metabolic (CKM)” health. As multifunctional drugs like HTD1801 continue to progress, he thinks doctors will move beyond the single-dimensional healing state of mind.

“My ideal scenario is that all physicians managing cardiovascular, metabolic, renal, hepatic, or even obesity issues would evaluate the patient with a holistic mindset,” he states, indicating the present siloed nature in medical practice. ” As an example eGFR monitoring is not always part of routine cardiological assessment, yet at the mechanistic level, cardiac and renal dysfunction are manifestations of the same underlying disease process — making an integrated view essential”

He pointed out an effective experiment he led while promoting dapagliflozin in China: needing cardiologists at partner health centers to determine clients’ eGFR throughout their assessments. By simply including this easy cross-disciplinary action, the variety of clients on standard directed medical treatment tripled within 6 months.

IV. A Buyer’s Lens: The Booming BD Activity in CKD and HighTide Therapeutics’ Confidence in Value Creation

As a core member of the business’s management group, Dr. Surmont likewise often takes a look at HighTide Therapeutics’ position through the lens of capital market and market characteristics.

Over the previous 2 years, the worldwide biopharmaceutical market has actually seen a rise in organization advancement (BD) activity in the CKD field. In 2025, Roche revealed a significant cooperation with Zealand Pharma valued at as much as $5.3 billion; international giants like Novartis, Boehringer Ingelheim, and Novo Nordisk have actually likewise been making substantial financial investments to protect superior possessions in the metabolic and kidney illness area.

Dr. Surmont, making use of his substantial international experience, has a clear continue reading this “land grab” phenomenon: “The core chauffeur is the huge earnings capacity and fast development in this field. 5 years earlier, the healing toolbox here was fairly restricted. Now, with development hits like GLP-1RAs and SGLT-2i’s, the kidney illness landscape has actually been improved, yet there stays a recurring threat is 60– 80% of the initial occasion concern.

He even more elaborated: “Even when patients are treated with four pillars of therapy (ACEi/ARBs, SGLT-2i’s, GLP-1RAs, MRAs), the complex underlying inflammatory mechanisms remain largely unaddressed, still leaving a significant gap in our ability to fully protect the kidney. This creates substantial pricing potential and broad combination therapy prospects for drugs with fundamentally new mechanisms like HTD1801.”

“Looking back at the history of SGLT-2 inhibitors, it took over a decade from approval to reaching 20%-25% guideline-directed clinical uptake. The slow progress was partly due to a lack of strong medical education and advocacy, and partly because of physicians and patients’ tendency to yield to the disease’s natural trajectory.”

Now, having actually taken the helm as CMO of HighTide Therapeutics, Dr. Filip Surmont is poised to challenge the status quo and break this complacency with strong medical information and a brand-new medical story. For this drug– born from Chinese development with a worldwide aspiration– the trip in the CKM field has actually only simply started.